Clinical Trial: High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Myocardial Fibrosis
Study Type: INTERVENTIONAL
Official Title: High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment
Brief Summary:
Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.The product was approved in 2022 by FDA to be used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).However, given its at least twofold higher…
Read more